Hadassah Sade, Managing Director at AstraZeneca Computational Pathology, shared a post on LinkedIn:
“The first ESMOAI25 Congress takes place this week in Berlin!
I’m thrilled AstraZeneca will be onsite presenting seven abstracts on new research on our advances in computational pathology.
Computational pathology is already driving advances in how we develop and use innovative cancer medicines. Our research at ESMO AI showcases the next wave, with the integration of foundation models, synthetic data generation and graph neural networks.
I want to share a huge thank you to everyone driving AstraZeneca’s computational pathology programs forwards, accelerating biomarker discovery and improving the accuracy and precision of our models to potentially improve patient outcomes.
Read more about AstraZeneca’s computational pathology approach in oncology R and D here.”
Read more posts featuring ESMOAI on OncoDaily.